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Abstract
Background: The surgical portosystemic shunts (PSS) are a time-proven modality for treating portal
hypertension. Recently, in the era of liver transplantation and the transjugular intrahepatic portosystemic
shunts (TIPS), use of the PSS has declined.
Objectives: This study was conducted to evaluate changes in practice, referral patterns, and short- and
longterm outcomes of the use of the surgical PSS before and after the introduction of the Model for
End-stage Liver Disease (MELD).
Methods: A retrospective analysis of 47 patients undergoing PSS between 1996 and 2011 in a single
university hospital was conducted.
Results: Subgroups of patients with cirrhosis (53%), Budd–Chiari syndrome (13%), portal vein throm-
bosis (PVT) (26%), and other pathologies (9%) differed significantly with respect to shunt type, Child–
Pugh class, MELD score and perioperative mortality. Perioperative mortality at 60 days was 15%.
Five-year survival was 68% (median: 70 months); 5-year shunt patency was 97%. Survival was best in
patients with PVT and worst in those with Budd–Chiari syndrome compared to other subgroups. Patency
was better in the subgroups of patients with cirrhosis and other pathologies compared with the PVT
subgroup. Substantial changes in referral patterns coincided with the adoption of the MELD in 2002, with
decreases in the incidence of cirrhosis and variceal bleeding, and increases in non-cirrhotics and
hypercoagulopathy.
Conclusions: Although the spectrum of diseases benefiting from surgical PSS has changed, surgical
shunts continue to constitute an important addition to the surgical armamentarium. Selected subgroups
with variceal bleeding in well-compensated cirrhosis and PVT benefit from the excellent longterm patency
offered by the surgical PSS.
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Introduction
Since its introduction into clinical practice in the mid-20th
century, surgical portosystemic shunts (PSS) have established
themselves as a time-proven method of treating gastro-
oesophageal variceal bleeding associated with end-stage liver
disease or extrahepatic portal hypertension. In the absence of
alternatives, the PSS represented the only viable treatment prior to
the introduction and widespread adoption of endoscopic interven-
tions such as endoscopic sclerotherapy and banding, followed later
by the perfection of orthotopic liver transplantation (OLT) along
with the emergence of the transjugular intrahepatic portosystemic
shunts (TIPS).
During the 1990s, several prospective randomized trials dem-
onstrated the superior longterm patency of surgical shunts and
their better prevention of recurrent bleeding, along with accept-
ably low operative morbidity and encephalopathy.1–3 These
reports, however, did not influence the rapid rise in the use of the
TIPS, which has become the standard treatment of choice for
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portal decompression, despite the fact that longterm outcomes
were inferior in both patency and survival.
Changing practice patterns, whereby cirrhotic patients were
almost exclusively treated by our gastrointestinal medicine and
radiology colleagues, along with the ‘minimally–invasive’ appeal
of endoscopic interventions and TIPS, caused an abrupt decline in
the use of surgical shunts. With the advent of OLT as
the definitive treatment for end-stage liver disease, many non-
surgeons have come to firmly believe that the role of shunts is
currently limited to that of a ‘bridge to transplant’ and, because
the TIPS is able to fulfil this role, there is minimal to no purpose
for surgical shunts.4 By contrast, it is the present authors’ belief
that a large patient population could be served appropriately
using the surgical PSS, including those with cirrhosis with com-
pensated liver function and patients with pre- and post-hepatic
portal hypertension who have minimal or no liver dysfunction. In
this patient population and in some patients in whom liver trans-
plantation is either premature or not indicated, the use of a sur-
gical shunt may be lifesaving and may offer excellent control of
symptoms and a positive longterm outcome. Removing shunt
operations from the surgical armamentarium is premature.
The purpose of this report is therefore several-fold. It aims to:
(i) reassess the safety of the surgical PSS, as well as their longterm
survival and patency; (ii) report change in referral practice before
and after the incorporation of the Model for End-stage Liver
Disease (MELD) score into the United Network for Organ
Sharing (UNOS) system; (iii) identify clinical subgroups of
patients who continue to benefit from the surgical PSS during the
current era of the TIPS and OLT, and (iv) review the existing
literature in support of the continued use of the surgical PSS in
current practice.
Materials and methods
After institutional review board approval had been obtained, a
retrospective review of a prospectively collected database was per-
formed. These data cover all patients who underwent the creation
of a surgical PSS at a single university hospital performed by a
single transplant and hepatobiliary surgeon during 1996–2011.
Surgical shunts were of three varieties: the side-to-side portocaval
shunt (SSPCS), the mesocaval with interposition H- or C-graft
shunt, and the central splenorenal shunt. The appropriate tech-
niques have been described elsewhere.5,6 Before and after the crea-
tion of the shunt, pressures in the portal vein and inferior vena
cava (IVC) were measured and portosystemic gradients were cal-
culated and recorded. All patients with known hypercoagulopathy
received anticoagulation immediately after the creation of the
shunt, and continued to receive warfarin indefinitely. Hyperco-
agulability was established by a history of thrombosis and protein
C/S deficiency, Factor V Leiden mutation, lupus inhibitor,
antiphospholipid syndrome or antithrombin III deficiency.
Baseline Doppler ultrasound was performed to assess shunt
patency prior to discharge and during follow-up at 3-month
intervals during the first year and yearly thereafter. If a shunt
occlusion or stenosis was suspected based on recurrent bleeding
or ascites, Doppler ultrasound was repeated and additional angi-
ographic studies were performed as appropriate. During the
follow-up period, patients with cirrhosis remained on a restricted
sodium intake of 2 g/day and restricted dietary protein of 60 g/
day. In patients with alcoholic cirrhosis, complete abstinence
from alcohol was emphasized repeatedly. An episode of encepha-
lopathy was defined on mental status examination, accompanied
by an elevated serum ammonia, or presence of asterixis on physi-
cal examination. Encephalopathy was graded as mild if it was
short-lived, corrected easily with dietary modification and an
increase in lactulose, and did not require hospitalization, and as
severe when it required hospitalization or prolonged manage-
ment with lactulose, an oral antibiotic and significant dietary
protein restriction.
Data points were collected on: age; gender; diagnosis and sur-
gical indications; comorbidities; presence of hypercoagulopathy;
type of portal hypertension (pre-, intra- or post-hepatic); preop-
erative Child–Pugh class and MELD score; liver chemistries; pres-
ence of gastro-oesophageal varices and number of episodes of
variceal bleeding and endoscopic interventions; type of shunt per-
formed; timing of procedure (emergent, urgent or elective); pre-
and post-shunt gradient (in mm saline); estimated blood loss (in
ml); results of liver biopsy; postoperative 30- and 60-day compli-
cations and mortality; length of hospital stay; shunt patency as
determined by Doppler ultrasound; presence of post-shunt
encephalopathy, ascites or re-bleeding; status of the patient at last
follow-up, and date of death.
Associations between various variables and diagnostic sub-
groups were calculated using Pearson’s chi-squared test and the
Kruskal–Wallis test for categorical and continuous variables,
respectively.
Patient survival and shunt patency were calculated using
Kaplan–Meier survival analysis. Differences between groups were
estimated by a log-rank test. Differences were considered signifi-
cant if associated with a P-value of < 0.05.
A multivariate logistic regression model (for operative mortal-
ity) and Cox proportional hazard models (for overall survival and
patency) were created to establish the associations of selected
variables with these outcomes. Associations among various vari-
ables were calculated using Pearson’s chi-squared test and the
Wilcoxon signed-rank test for categorical and continuous vari-
ables, respectively.
Results
The study included 47 PSS patients treated over a 15-year period
(1996–2011). Detailed patient demographic and clinical charac-
teristics are presented in Table 1. The mean age of the patients was
44.6  18.6 years. The youngest patient was a 7-month-old baby
boy with Krabbe disease and a history of a bone marrow trans-
plant with subsequent veno-occlusive disease (VOD) and massive
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ascites; the oldest was a 72-year-old man with non-alcoholic stea-
tohepatitis (NASH) cirrhosis and variceal bleeding.
Four definite subgroups were identified, comprising patients
with: (i) cirrhosis (n = 25, 53%) (alcoholic, 17%; hepatitis C, 11%;
cryptogenic and other cirrhosis, 26%); (ii) Budd–Chiari syn-
drome (n = 6, 13%); (iii) portal vein thrombosis (PVT) (n = 12,
26%), and (iv) other pathologies (n = 4, 9%), including congenital
hepatoportal sclerosis, nodular regenerative hyperplasia, VOD
and congenital hepatic fibrosis.
When grouped according to the presence or absence of cirrho-
sis, patients with cirrhosis comprised 53% and those without
cirrhosis 47% (diagnostic subgroups ii–iv) of the study cohort. Of
note, eight of 12 patients with cryptogenic cirrhosis were obese
and had diabetes and would be reclassified as having NASH cir-
rhosis according to current diagnostic criteria.
Fourteen patients (30%) were either known to have hyperco-
agulopathy or were diagnosed as such during their hospital
workup.
Thirty-eight patients (80%) showed evidence of gastro-
oesophageal varices on oesophagogastroduodenoscopy or com-
puted tomography. Of these, 34 (72%) had clinically significant
bleeding (mean of 2.5 bleeding events per patient) and 26 (55%)
underwent endoscopic intervention (mean of 1.96 interventions
per patient).
Thirty-day operative morbidity was 43%. The majority of mor-
bidity referred to ascites-related wound complications [ascites
leak from the wound in the early postoperative period (n = 3),
superficial wound infection (n = 7), and wound dehiscence with
intra-abdominal abscess (n = 2)]. Other complications were: acute
kidney injury, worsening ascites with IVC compression treated
with IVC stenting and ascites resolution (n = 1); coecal perfora-
tion (n = 1); methicillin-resistant Staphylococcus aureus (MRSA)
pneumonia requiring ventilator support (n = 1); new-onset atrial
fibrillation (n = 1); recurrent pericardial effusion requiring a peri-
cardial window (n = 1), and line infection (n = 1). Early postop-
erative shunt thrombosis with resultant recurrent variceal
bleeding was identified in one patient who had a central spleno-
renal shunt in the setting of a hypercoagulable state not recog-
nized prior to the first shunt. The recurrent bleeding was
successfully treated by shunt revision on postoperative day 7.
Perioperative mortality rates at 30 days and 60 days were 6%
(n = 3) and 15% (n = 7), respectively. Mortality details are pre-
sented in Table 2. In-hospital mortality in the emergent and
urgent categories grouped together comprised of three of 15
patients (20%). The mean and median length of stay were 19.5
days and 10 days, respectively.
Overall survival was 79%, 72%, 68% and 48% at 1, 3, 5 and 7
years, respectively. A total of 18% of patients survived 10 years
(Fig. 1). Median survival was 70 months with a mean follow-up of
41 months.
Overall primary shunt patency was 97% during the first 5-year
interval and 58% during the second 5-year interval (Fig. 2).
Secondary-assisted patency was 70% at 10 years, as one hyperco-
Table 1 Patient demographics and clinical characteristics of patients
submitted to portosystemic shunt surgery
Study period 1996–2011
Total number of patients 47
Age, years, mean  SD 44.6  18.6
Male : female ratio 0.53 : 0.47
Hypercoagulopathy, n (%) 14 (30%)
Evidence of gastro-oesophageal varices, n (%) 37 (80%)
Clinically significant bleeding, n (%) 34 (72%)
Oesophagogastroduodenoscopy, n (%) 25 (55%)
Cirrhosis/no cirrhosis, n (%) 25 (53%)/22 (47%)
Diagnostic subgroups, n (%)
Cirrhosis 25 (53%)
EtOH 8 (17%)
Hepatitis C 5 (11%)
Cryptogenic and other 12 (26%)
Budd–Chiari syndrome 6 (13%)
Portal vein thrombosis 12 (26%)
Othera 4 (9%)
Type of portal hypertension, n (%)
Pre-hepatic 13 (28%)
Intra-hepatic 27 (57%)
Post-hepatic 5 (11%)
Pre- and post-hepatic and pre-and
intra-hepatic
2 (4%)
Child–Pugh class, n (%)
A 24 (51%)
B 19 (40%)
C 4 (9%)
Era, n (%)
Pre-MELD 25 (53%)
Post-MELD 22 (47%)
Timing of operation, n (%)
Elective 32 (70%)
Emergent (24–48 h) 8 (17%)
Urgent (during index admission) 7 (13%)
Type of shunt, n (%)
SSPCS 35 (74%)
Mesocaval 5 (11%)
Central splenorenal 7 (15%)
Portocaval gradient, mm saline, mean  SD
Before shunting 258.3  89.4
After shunting 10.4  27.17
Difference 248.8  87.9
Mortality, n (%)
30-day 3 (6%)
60-day 7 (15%)
aCongenital hepatoportal sclerosis, nodular regenerative hyperplasia,
Krabbe disease, congenital hepatic fibrosis.
SD, standard deviation; MELD, Model for End-stage Liver Disease;
SSPCS, side-to-side portocaval shunt.
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Table 2 Mortality details in patients submitted to portosystemic shunt surgery (n = 47)
Subject Sex, age,
years
Diagnosis MELD
score
Child–Pugh
class
Type of shunt Mortality
time, PoD
Mortality details
1 M, 52 Acute massive GI bleed,
EToH cirrhosis, need for
urgent shunt
15 C Emergency
SSPCS
2 Significant bleeding and
coagulopathy intra- and
postoperatively despite
massive transfusions and
factors
2 F, 30 Budd–Chiari syndrome,
fulminant liver failure,
massive ascites, brain
oedema, unsuccessful
angioplasty
37.8 C Emergency
SSPCS
4 Fulminant liver failure, brain
oedema, emergent shunt,
postoperative herniation,
brain death
3 M, 35 Budd–Chiari syndrome,
hypersplenism,
polycythemia vera
16.67 B SSPCS 10 Intractable third spacing,
ascites, hypotension,
resistant to pressors and
albumin, suspected to be
caused by TRALI,
hepatorenal syndrome,
haemodialysis, ARDS
4 F, 46 Alcoholic cirrhosis,
oesophageal bleeding
bleed, need for emergent
shunt
10 B Emergency
SSPCS
39 Postoperative ascites, recurrent
paracentesis,
encephalopathy, EtOH
withdrawal, re-exploration for
possible shunt revision (shunt
was patent), repeat upper GI
bleed despite repeat banding
and splenic artery
embolization, massive
transfusion
5 F, 52 Budd–Chiari syndrome,
thrombosis of right and
main hepatic veins,
stenosis of left hepatic
vein, polycythemia vera
9.5 B SSPCS 51 Tense ascites, IVC clotting
despite anticoagulation IVC
stenting, IVC and shunt
thrombectomy, revision of
shunt to H-graft, bleeding
duodenal ulcer, ARF,
intra-abdominal bleed ¥ 2,
erosion of H-graft
6 M, 62 Myeloproliferative
syndrome, polycythemia
vera, Budd–Chiari
syndrome, multifocal
non-occlusive PVT,
recurrent intractable
ascites
21.5 C H-graft
portocaval
shunt, portal
vein
thrombectomy
53 Shunt thrombosis caused by
extrinsic compression
(caudate lobe), TIPS
placement, recurrent ascites
leak, malnutrition, liver
failure, resistant
hypercoagulable state (Jak 2
mutation, ATIII deficiency,
Factor 7,8,9), failure to
improve, withdrawal of care
7 F, 29 Budd–Chiari syndrome,
factor 5 Leiden,
polycythemia vera
20 C SSPCS 63 Wound dehiscence,
re-exploration, shunt
thrombosis, despite
anticoagulation,
thrombectomy ¥2
suprahepatic IVC stenting,
shunt revision to H-graft,
portal vein thrombectomy,
hepatocellular atrophy with
progressive hepatocellular
collapse, liver failure, renal
failure, OLT, hypotension,
hypothermia, cardiac arrest
M ELD, Model for End-stage Liver Disease; PoD, postoperative day; M, male; F, female; GI, gastrointestinal; SSPCS, side-to-side portocaval shunt;
TRALI, transfusion-related acute lung injury; ARDS, adult respiratory distress syndrome; EtOH, alcohol; IVC, inferior vena cava; ARF, acute renal
failure; ATIII, antithrombin III; PVT, portal vein thrombosis; OLT, orthotopic liver transplantation; TIPS, transjugular intrahepatic portosystemic shunts.
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agulable patient experienced occlusion of a central splenorenal
shunt after 6 years and underwent the successful creation of a
mesocaval shunt with an interposition H-graft that remained
patent 3 years afterwards.
Eleven patients (23%) had a single episode of mild post-shunt
encephalopathy that was short-lived, was corrected easily with
diet modification and an increase in lactulose, and did not
require hospitalization; one patient had an episode of moderate
encephalopathy that required brief hospitalization in addition to
these measures. There were no episodes of severe or prolonged
encephalopathy.
There were three episodes of re-bleeding during the follow-up
period. One case signified shunt occlusion that was corrected with
revision. The second patient bled from a duodenal ulcer, and the
third patient had an emergency surgical shunt for bleeding varices
and bled in the immediate postoperative period, with spontane-
ous resolution.
Associations among selected variables and
diagnostic subgroups
When patients were stratified by diagnostic subgroups, various
associations emerged (Table 3). There was a significant difference
in age distribution, as patients with causes other than cirrhosis
were on average 15–37 years younger than those with cirrhosis (P
= 0.016). Hypercoagulopathy was found to be strongly associated
with the Budd–Chiari syndrome and PVT subgroups (P < 0.001).
Budd–Chiari syndrome was associated with a significantly higher
MELD score and Child–Pugh classes B and C (P < 0.017 and P <
0.001, respectively). These patients also suffered from significantly
higher 60-day mortality (P < 0.001). There was no difference in
postoperative complications among the subgroups. Although
patients with cirrhosis and PVT presented with gastro-
oesophageal variceal bleeding, patients with Budd–Chiari syn-
drome and those in the subgroup with other causes of portal
hypertension did so less frequently (P < 0.001), with ascites as the
major manifestation of portal hypertension. An SSPCS was per-
formed in 100% of patients with cirrhosis, Budd–Chiari syn-
drome and ‘other’ pathologies, whereas patients with PVT
underwent a mesocaval shunt (42%) or central splenorenal shunt
(58%) procedure (P < 0.001). No association was found between
the urgency of the procedure and rates of perioperative morbidity
or mortality (P = NS). During the pre-MELD era, patients with
cirrhosis had constituted the majority of shunt patients (68%);
after the adoption of the UNOS allocation of liver allografts by
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Figure 1 Overall survival (n = 47)
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MELD score, the ratio reversed and non-cirrhotic patients came
to represent the largest subgroup (64%) (P = 0.03). Portal hyper-
tension associated with hypercoagulopathy became a more fre-
quent indication for PSS after the introduction of MELD criteria
(P = 0.028), whereas during this era variceal bleeding became a
rare indication (P = 0.004).
Survival stratified by diagnostic subgroups
When overall survival was stratified by diagnostic subgroups,
patients with PVT were found to fare best (P = 0.006) and
patients with Budd–Chiari syndrome to fare worst (P = 0.02)
compared with the rest of the subgroups (Fig. 3). The poor sur-
vival of patients with Budd–Chiari syndrome corresponded to
the significant postoperative mortality in this subgroup. Five of
six patients with Budd–Chiari syndrome died in the hospital.
Three of them had Child–Pugh class C cirrhosis and high MELD
scores signifying advanced disease. One patient had fulminant
hepatic failure and brain oedema and had been referred very late;
another patient had shunt thrombosis caused by extrinsic com-
pression by a hypertrophied caudate lobe and recalcitrant hyper-
coagulable and premalignant state, and the last patient developed
recurrent shunt thrombosis requiring revision with a cryopre-
served femoral vein H-graft and portal vein thrombectomy and
later salvage OLT secondary to progressive liver failure, which led
to death. An additional patient died despite aggressive measures
including full anticoagulation, IVC stenting, IVC and shunt
thrombectomy, and revision of the shunt with an internal jugular
vein H-graft. This patient developed a bleeding duodenal ulcer,
acute renal failure, and died of intra-abdominal bleeding second-
ary to the erosion of his duodenal ulcer into the H-graft. One
remaining patient with Budd–Chiari syndrome remained alive at
>13 years after her shunt operation. Overall, the survival of
patients without cirrhosis did not differ statistically from that of
their counterparts with cirrhosis (P = 0.15), nor was there any
difference in overall survival between patients operated before
and after the introduction of the MELD criteria. Of note, only
one patient (noted above) in the entire series underwent OLT for
subsequent treatment.
Longterm patency of the PSS
The patency of shunts stratified by diagnostic subgroups is illus-
trated in Fig. 4. In terms of longterm shunt patency, patients in the
cirrhosis and ‘other’ pathologies subgroups fared better than those
in the PVT subgroup (P = 0.04).
0 12 24 36 48 60 72 84 96 108 120 132 144 156
39 17 12 8 6 6 3 3 3 1 1 1 1 1
0.00
0.25
0.50
0.75
1.00
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Figure 2 Overall shunt patency (n = 39)
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Univariate and multivariate analysis
60-day operative mortality
On univariate analysis, a higher MELD score (P = 0.024), intra-
operative transfusion (P = 0.041), Child–Pugh class B or C (P <
0.001) and the presence of Budd–Chiari syndrome (P < 0.001)
were predictive of increased 60-day mortality (Table 4). In a mul-
tivariate model, MELD score was found to be significant [odds
ratio (OR) 1.36; P = 0.03]. Budd–Chiari syndrome was so associ-
ated with 60-day mortality that a model of convergence could not
be created.
Longterm survival
When perioperative mortality was excluded, multivariate analysis
showed PVT, compared with EtOH cirrhosis, to be associated with
increased longterm survival [hazard ratio (HR) 0.040; P = 0.037],
whereas Child–Pugh class C status, compared with that of
Child–Pugh class A, was associated with decreased longterm sur-
vival. (HR = 59; P = 0.015).
Longterm patency
On multivariate analysis mesocaval (HR = 116) and central
splenorenal (HR = 22) shunts tended to have decreased longterm
patency compared with the SSPCS, although these differences did
not reach statistical significance (P = 0.065 and P = 0.091, respec-
tively). This is likely to reflect the high shunt thrombosis rate in
patients with Budd–Chiari syndrome and SSPCS and the rela-
tively smaller numbers of patients who did not receive an SSPCS.
Discussion
The current study summarizes the present authors’ experience
with surgical PSS during a time when multiple non-invasive strat-
egies and liver transplantation have become de facto modalities for
Table 3 Associations among selected variables and diagnostic subgroups in patients submitted to portosystemic shunt surgery (n = 47)
Cirrhosis
(combined)
(n = 24)
Budd–Chiari
syndrome
(n = 6)
Portal vein
thrombosis
(n = 12)
Other causes of
portal hypertension
(n = 4)
P-value
Age, years, median (IQR) 53 (47–61) 38 (31–61) 37 (16–53) 14 (6–32) 0.016
Sex, n (%) 0.6
Female 11 (44%) 4 (67%) 6 (50%) 1 (25%)
Male 14 (56%) 2 (33%) 6 (50%) 3 (75%)
Hypercoagulopathy, n (%) <0.001
No 25 (100%) 1 (17%) 4 (33%) 4 (100%)
Yes 0 5 (83%) 8 (67%) 0
Child–Pugh class, n (%) 0.006
A 15 (60%) 0 7 (58%) 2 (50%)
B 9 (36%) 3 (50%) 5 (42%) 2 (50%)
C 1 (4%) 3 (50%) 0 0
MELD score, median (IQR) 10.9 (8.8–13.7) 19.4 (17.2–22.6) 9.2 (7.8–13.55) 10.6 (10.0–11.3) 0.023
GO variceal bleeding episodes,
n, median (IQR)*
2 (1–3) 0 1.5 (1–3) 0 <0.001
Type of shunt, n (%) <0.001
Side-to-side portocaval 25 (100%) 6 (100%) 0 4 (100%)
Mesocaval 0 0 5 (42%) 0
Central splenorenal 0 0 7 (58%) 0
60-day complications, n (%) 0.8
No 14 (56%) 4 (67%) 6 (50%) 3 (75%)
Yes 11 (44%) 2 (33%) 6 (50%) 1 (25%)
60-day mortality, n (%) <0.001
No 23 (92%) 1 (17%) 12 (100%) 4 (100%)
Yes 2 (8%) 5 (83%) 0 0
Period, n (%) 0.03
Pre-introduction of MELD 17 (68%) (Combined) 8 (36%)
Post-introduction of MELD 8 (32%) (Combined) 14 (64%)
IQR, interquartile range; Model for End-stage Liver Disease; GO, gastro-oesophageal.
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indications previously reserved for surgical shunts. Despite the
fact that only a small fraction of cirrhosis patients with bleeding
will ultimately undergo liver transplantation after the TIPS place-
ment (3–10% in most series),5–8 an unsubstantiated belief that
those patients will be candidates for possible liver transplant has
resulted in the adoption of the TIPS as the decompressive shunt of
choice and as a bridge to transplant by clinical decision makers. In
a randomized controlled trial (RCT) reported by Orloff (MJ)
et al., which compared endoscopic sclerotherapy with emergency
PSS in 211 unselected consecutive patients with advanced cirrho-
sis and bleeding oesophageal varices, only 6% were referred for
OLT and only 2% underwent OLT, with worse 1- and 5-year
survival rates.9 In addition, this analysis was supplemented by
1300 non-randomized cirrhosis patients who previously under-
went SSPCS with 100% follow-up, of whom only 3.8% were
referred for and only 1.5% actually underwent OLT, again with a
worse 5-year survival rate.9
As the number of TIPS performed has increased, the number of
surgical shunts has reciprocally decreased and, as a result, current
surgical trainees are neither exposed to these operations nor com-
fortable with treating this group of patients, either surgically or
medically. A review of case logs maintained by the Accreditation
Council for Graduate Medical Education (ACGME) over the past
10 years reveals that the average number of PSS performed by a
graduating resident ranged between one and five and averaged 0.3
per resident during 2000–2005 and 0.1 during 2005–2012.10 In
addition, since February 2002, when UNOS adopted a modified
version of the original MELD (Proposed Amended UNOS Policy
3.6. 2002; http://optn.transplant.hrsa.gov/policiesAndBylaws/
policies.asp) in order to allow the allocation of liver organs to
sicker patients, the volume of patients with cirrhosis referred for
surgical shunts has declined in parallel. As sicker cirrhosis patients
have become eligible for transplantation and have meanwhile
been temporized by other means, the need for surgical shunts has
continued to decrease further. This shift has contributed to the
perception of surgical shunts in general as irrelevant.
In the present authors’ experience, although cirrhosis patients
constituted the majority of shunt patients (68%) prior to the
introduction of the MELD system, after the adoption of MELD by
UNOS the ratio reversed and patients without cirrhosis came to
represent the majority (64%) (P = 0.03). Conditions associated
with hypercoagulopathy came to represent a more frequent indi-
Figure 3 Survival stratified by diagnostic subgroups (n = 47)
Notes: Difference between groups was estimated by a log-rank test. P = 0.006 PV thrombosis versus cirrhosis, and P = 0.02 PV thrombosis
versus Budd -Chiari and cirrhosis versus Budd -Chiari. ‘Other’ subgroup is not large enough for statistical significance.
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cation for the SSPCS during the ‘post- MELD’ era, whereas
variceal bleeding constituted a rare indication in this period.
The current study has identified four distinct diagnostic sub-
groups, each of which demonstrates unique patient characteristics
and associated factors. These subgroups (comprising patients
with, respectively, cirrhosis, Budd–Chiari syndrome, PVT and
‘other’ pathologies) differed in approach, complications and
short- and longterm prognosis. Cirrhosis patients were on average
15–37 years older than patients without cirrhosis. As expected,
hypercoagulopathy was found to be strongly associated with
Budd–Chiari syndrome and PVT. Although patients with cirrho-
sis and PVT frequently presented with gastro-oesophageal varices
and bleeding, patients with Budd–Chiari syndrome and other
pathologies presented mostly with ascites. In the present series,
Budd–Chiari syndrome was associated with significantly higher
MELD score and Child–Pugh class B or C status and also with
significantly higher 60-day mortality. One of the earliest series of
Budd–Chiari syndrome patients treated with surgical shunts was
reported by Cameron et al. and indicated modest results.11 Only
eight of 12 patients survived to discharge; of those, three devel-
oped shunt thrombosis shortly thereafter, and the remaining five
patients had a patent shunt. Importantly, however, liver architec-
ture normalized in patients with patent shunts who had not yet
developed cirrhosis. Later, with early intervention, perfection of
the surgical technique, and a combination of an SSPCS with
a cavoatrial shunt, Orloff (MJ) et al. achieved significantly
improved results and demonstrated that effective early decom-
pression of the liver is imperative to halt the progression of cir-
rhosis in Budd–Chiari syndrome.12,13
The present results of the surgical treatment of Budd–Chiari
syndrome (five of six in-hospital deaths) are discouraging. The
following explanations are proposed. These patients were referred
late for surgical shunt procedures, with significant liver and sys-
temic decompensation, and higher MELD scores than patients in
the other subgroups. They might possibly have been salvaged by
early referral. The common practice has been medical treatment
with anticoagulation and thrombolysis: this is known as a ‘step-
wise approach’.14–16 It should be noted that patient deaths that
occur as a result of difficult-to-control hypercoagulability causing
recurrent shunt thrombosis would most likely also result in TIPS
thrombosis, should this route have been elected. As a result, in
light of the high mortality risk affecting patients with Budd–
Figure 4 Shunt patency stratified by diagnostic subgroups (color-coded) (n = 39)
Notes: Difference between groups was estimated by a log-rank test. P = 0.005 cirrhosis versus Budd -Chiari and P = 0.04 cirrhosis versus
PV thrombosis. ‘Other’ subgroup is not large enough for statistical significance.
HPB 489
HPB 2014, 16, 481–493 © 2013 International Hepato-Pancreato-Biliary Association
Chiari syndrome and established liver decompensation, the
current authors recommend neither surgical shunt nor TIPS
surgery for this subgroup. These patients should be promptly
referred for definitive therapy with OLT.
All patients in the cirrhosis, Budd–Chiari syndrome and ‘other’
pathology subgroups received SSPCS, whereas patients with PVT
received mesocaval (42%) and central splenorenal (58%) shunts.
Although the proponents of distal splenorenal shunts argue that
they achieve effective portal decompression without a high inci-
dence of encephalopathy,3,17,18 it is the present authors’ experience
that central shunts, in particular the SSPCS, are technically
straightforward, achieve effective portal decompression and have
high longterm patency. The ensuing encephalopathy is usually
mild and easily managed. The further advantage of the SSPCS is
its use in the treatment of intractable ascites, whereas the distal
splenorenal shunt often makes the ascites worse. The goal of the
present authors was to create an SSPCS when possible and to use
other types of central shunts when an SSPCS was not an option, as
in patients with complete PVT. However, there was no difference
in postoperative complications between patients with different
types of central shunts, as shown in previous reports.19–21 The
frequency of encephalopathy in the present series was low (about
20% mild encephalopathy) and comparable with those reported
in other series of surgical shunt patients (3.0–18.75%)22–24 and
lower than that associated with the TIPS (30%),25 and, when diag-
nosed, was easily managed.
In the present series, rates of 30-day and 60-day operative
mortality were 6% (n = 3) and 15% (n = 7), respectively, and
were similar or lower than some of those reported for surgical
shunts in the literature.20,21,23,24 The majority (70%) of the
present patients were operated electively and the remainder
underwent urgent or emergent surgery. Prohibitively high mor-
tality rates after emergent surgical shunts, reaching 50%, have
historically represented a reason to choose the TIPS in acute
variceal haemorrhage. However, the RCT of emergency endo-
scopic sclerotherapy versus emergency PSS for acute bleeding of
oesophageal varices reported by Orloff (MJ) et al. provided
uniquely excellent results, with 1-, 5-, 10- and 15-year survival
rates of 81%, 73%, 46% and 46%, respectively, in the shunt
group and much inferior survival rates of 72%, 21%, 9% and
9%, respectively, in the sclerotherapy group.26,27 In this rand-
omized trial, 85% of shunt patients survived to discharge. The
present study found a 60-day mortality rate of 20% in the
emergent/urgent subgroup, which compares favourably with
those of other reports. No association between the urgency of
the procedure and rates of perioperative morbidity or mortality
emerged in the present data. In the present series, univariate
analysis showed 60-day mortality to be associated with higher
MELD score, intraoperative transfusion, Child–Pugh class B or
C status and the presence of Budd–Chiari syndrome. However,
in the multivariate model only the association with MELD score
was found to be significant. The presence of Budd–Chiari syn-
drome was nearly universally associated with 60-day mortality;
therefore, a model of convergence could not be created. The
present results may suggest that it is not the urgency of the
operation that puts the patient at higher risk, but, rather, the
severity of disease along with liver decompensation.
In the present study, overall survival amounted to 79%, 72%,
68% and 48% at 1, 3, 5 and 7 years, respectively, and 18% of
patients survived 10 years. Median survival was 70 months, which
Table 4 Multivariate analysis of 60-day mortality, overall survival and
longterm patency in patients submitted to portosystemic shunt
surgery (n = 47)
60-day mortality
Variable OR 95% CI P-value
Age (per year) 0.993 0.937–1.06 0.792
MELD (per point) 1.366 1.063–1.959 0.032
EBL (per 100 ml) 1.051 0.956–1.234 0.523
Transfusion (per unit) 1.052 0.555–1.825 0.853
Elective (versus urgent)
surgery
1.137 0.077–25.70 0.924
Longterm survival
Variable HR 95% CI P-value
Age (per year) 1.030 0.984–1.079 0.207
Sex (male versus female) 0.321 0.060–1.714 0.184
Child–Pugh score
(reference: A)
B 1.106 0.252–4.860 0.894
C 59.364 2.183–1614.688 0.015
EBL (per 100 ml) 1.043 0.928–1.171 0.479
MELD (per point) 0.864 0.698–1.070 0.182
Diagnosis (reference:
EtOH cirrhosis)
Budd–Chiari syndrome 0.268 0.014–4.998 0.378
Cryptogenic and other
cirrhosis
0.113 0.009–1.489 0.097
Hepatitis C cirrhosis 0.470 0.055–4.050 0.492
Other 0.675 0.053–8.641 0.763
Portal vein thrombosis 0.040 0.002–0.821 0.037
Post-MELD (versus
pre-MELD)
1.122 0.251–5.024 0.880
Longterm patency
Variable HR 95% CI P-value
Age (per year) 1.016 0.948–1.088 0.655
Hypercoagulopathy 0.484 0.030–7.743 0.608
MELD (per point) 1.478 0.941–2.323 0.090
Shunt type (reference:
portocaval)
Mesocaval shunt 116.680 0.744–18298.675 0.065
Splenorenal shunt 22.430 0.610–824.879 0.091
OR, odds ratio; 95% CI, confidence interval; HR, hazard ratio; MELD,
Model for End-stage Liver Disease; EBL, estimated blood loss.
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is comparable with or superior to survival in other surgical shunt
series, but significantly longer than in patients submitted to TIPS
procedures. In a study by Rosemurgy et al. of H-graft portocaval
shunts, the survival of all patients grouped together (Child–Pugh
classes A–C) was 68% at 2 years and 47% at 5 years, and median
survival was 52 months.24,28 Patients with a more favourable risk
profile (Child–Pugh class A or B cirrhosis) were the subject of a
comparative study performed by Helton et al.,19 who reported a
2-year survival of 90% in a subgroup of patients with well-
compensated liver disease undergoing surgical PSS. Orloff (MJ)
et al. reported longterm survival of 78%, 71% and 57% at 5 years,
10 years and 15 years, respectively, in emergent portocaval shunt
patients, demonstrating enviable results unmatched by anyone
else.29 In addition, Orloff (MJ) et al. have shown that the surgical
PSS is far superior to endoscopic sclerotherapy or the TIPS in
two randomized prospective trials in the treatment of bleeding
oesophageal varices.21,26
Pooled together, the survival of non-cirrhotic patients was not
statistically different from their cirrhotic counterparts, nor was
there any difference in the overall survival between ‘pre-MELD’
and ‘post- MELD’ era. However, when overall survival was strati-
fied by diagnostic subgroups, patients with PVT fared better than
other subgroups.
The current study demonstrated an overall primary shunt
patency of 97% during the first 5-year interval and of 58% at 6–10
years. Secondary-assisted patency was 70% at 10 years. Rosemurgy
et al. reported an H-graft median patency period of 42 months28
(about 70% at 2 years and 45% at 5 years), whereas Orloff (MJ)
et al. reported SSPCS patency of >95% at more than 10 years of
follow-up.29 Multivariate analysis of data for the present patients
showed that mesocaval and central splenorenal shunts tended to
have decreased longterm patency compared with portocaval
shunts, but the difference was not significant. The longterm
patency of shunts placed in the cirrhosis and ‘other’ pathology
subgroups fared better than that in patients with PVT. Although it
was not the purpose of the present study to compare survival or
patency in similar patients after TIPS procedures, a review of the
recent literature found no study with outcomes after TIPS match-
ing the longterm patency of surgical shunts in the present study.
In our institution, surgical PSS are performed alongside the
liver transplant programme. During the past two decades, signifi-
cant changes in referral pattern, patient demographics, and in the
indications for and types of shunts performed have been seen. The
shift in referral pattern, whereby the majority of referrals prior to
2002 concerned patients with cirrhosis, and the majority after
2002 concerned non-cirrhotic patients with hypercoagulopathy
and PVT may reflect several issues, including the more frequent
use of endoscopic management and/or TIPS to control variceal
bleeding coupled with the new MELD allocation strategy, which
results in the referral of cirrhosis patients with bleeding varices
and refractory ascites to interventional radiologists and their
placement on a transplant list, whereas subgroups of patients with
preserved liver function and portal hypertension are referred for a
surgical shunt procedure. In the present cohort, many patients in
the latter group had hypercoagulopathy and PVT, a combination
that precludes the placement of a TIPS as a result of technical
inability and patency concerns. These considerations, together
with the fact that many of these patients were not in need of a liver
transplant, deemed the surgical shunt particularly appropriate.
Several studies have been performed to directly compare the
TIPS and different surgical shunts19,23,24 and have been summa-
rized in a meta-analysis carried out by Clark et al.30 The latter
included three prospective randomized trials and one retrospec-
tive case–control study, comprising 314 patients, and included
both selective and non-selective surgical shunts in patients with
cirrhosis of Child–Pugh class A or B status. The study showed
equal 30-day mortality and survival at 1 year; however, there was
a clear survival advantage at 2 years for patients undergoing sur-
gical shunts. Three of four trials found significantly higher rates of
rehaemorrhage after TIPS, resulting in a higher rate of TIPS
failure at 2 years, which translated into more hospital readmis-
sions, greater consumption of resources, higher costs, and a need
for better longterm surveillance and care of TIPS patients. A
recent RCT comparing surgical shunts with TIPS in unselected
patients with cirrhosis over a period of >10 years again found that
patients with surgical shunts had significantly better shunt
patency, fewer re-bleeding events and re-interventions, less post-
shunt encephalopathy and better survival across all Child–Pugh
classes, in addition to lower overall costs.21 Most of the patients in
the present study, particularly post-MELD, had preserved liver
function and thus favoured the patency advantage of surgical
shunts.
The present study has numerous limitations. Firstly, it is a retro-
spective review and is subject to all the disadvantages inherent in
such a study design. Secondly, the number of patients is not large.
Accordingly, each diagnostic subgroup has limited reliability of
survival and patency analysis, particularly at the tails of the
Kaplan–Meyer curves as numbers decrease further. However, the
evaluation of diagnostic subgroups was of particular interest
because it elucidates significant differences in approach, treatment
and outcomes. Thirdly, comparing the survival and patency of
subgroups with different disease aetiologies and other characteris-
tics is less powerful; instead, a more worthwhile comparison would
have been based on Child–Pugh class, MELD score and similar
disease aetiology. However, this comparison, although more rel-
evant statistically, would be of limited clinical interest because not
only are the numbers of the present patient groups insufficient to
warrant this type of study, but such research has been previously
conducted and reported in the published literature.
In conclusion, the present authors acknowledge the fact that
despite certain shortcomings, the TIPS is probably here to stay and
will continue to be considered as a first-line therapy in patients
with advanced cirrhosis and variceal bleeding or refractory ascites
failing endoscopic or medical therapies. The use of the TIPS as a
bridge to OLT in the short term is acceptable. However, this
approach should not be extrapolated to subgroups of patients
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with preserved liver function and a good life expectancy, such
as those with non-cirrhotic portal hypertension and well-
compensated cirrhosis, who would best be served by a surgical
PSS. The present report showed that surgical shunts in this popu-
lation can be performed with low operative morbidity and mor-
tality and may offer unmatched longterm patency, the prevention
of recurrent events and, in consequence, possibly improved
survival. Surgical shunts in advanced Budd–Chiari syndrome are
associated with high mortality and those patients should be con-
sidered for transplant. Liver biopsy prior to proposing a surgical
shunt will help to exclude this high-risk group.
Whether this report will change current practice when surgeons
are no longer trained to carry out this procedure is questionable
and beyond the scope of this discussion. However, it is to be hoped
that the present results will overcome inertia of thinking with
respect to the TIPS and alert treating clinicians to refer the appro-
priate subgroup of patients for whom the longterm benefits of
surgical shunts are clear to the appropriate specialist surgeons.
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